Survivorship Guidance for Patients with Colorectal Cancer

  • Jillian Simard
  • Suneel Kamath
  • Sheetal KircherEmail author
Lower Gastrointestinal Cancers (AB Benson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lower Gastrointestinal Cancers

Opinion statement

Effective therapy for treatment of colorectal cancer includes comprehensive and evidence-based therapies that may include a combination of surgery, chemotherapy, targeted therapy, and/or radiation. However, in order to provide patients with the highest quality of care, providers must consider all aspects of survivorship care including: surveillance for recurrence/second primaries, genetic counseling, psychosocial/physical late effects of cancer and its therapies, and preventative lifestyle strategies. Health systems, providers, and researchers need to identify systematic methods of addressing the unique needs of the survivorship population that include multidisciplinary teams including supportive oncology (i.e., psychologists, social workers), specialties (i.e., cardiology), and primary care physicians.


Colorectal neoplasms Survivorship Neoplasms Cancer Diet Exercise Recurrence Genetics 


Compliance with Ethical Standards

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Noone AM, Howlader N, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2015. Published 2018. Accessed November 18, 2018.
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. Scholar
  3. 3.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;116(suppl 12):544–17. Scholar
  4. 4.
    Bailey CE, Hu C-Y, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of Colon and Rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150(1):17–22. Scholar
  5. 5.
    • National Comprehensive Cancer Network. Colon Cancer (version 4.2018). Accessed November 11, 2018. This is the most recent version of the NCCN guidelines for colon cancer that guides diagnosis and management of cancer.
  6. 6.
    • National Comprehensive Cancer Network. Rectal Cancer (Version 3.2018). Accessed November 11, 2018. This is the most recent version of the NCCN guidelines for rectal cancer that guides diagnosis, and management of cancer.
  7. 7.
    • El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65(6):427–55. These are the comprehensive recommendations from the American Cancer Society specifically addressing clinical survivorship needs for colorectal cancer.CrossRefGoogle Scholar
  8. 8.
    Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31(35):4465–70. Scholar
  9. 9.
    Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297–316. Scholar
  10. 10.
    Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23(25):6126–31. Scholar
  11. 11.
    Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol. 2007;30(4):333–9. Scholar
  12. 12.
    Wiltink LM, Nout RA, Fiocco M, Meershoek-Klein Kranenbarg E, Jürgenliemk-Schulz IM, Jobsen JJ, et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J Clin Oncol. 2015;33(15):1640–6. Scholar
  13. 13.
    Martling A, Smedby KE, Birgisson H, Olsson H, Granath F, Ekbom A, et al. Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. Br J Surg. 2016;104(3):278–87. Scholar
  14. 14.
    • Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal Cancer: European Society for Medical Oncology clinical practice guidelines. J Clin Oncol. 2015;33(2):209–17. This is a guidance document for clinicians to diagnosis and follow patients with hereditary syndromes.
  15. 15.
    Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. Guideline development group, American College of Medical Genetics and Genomics Professional Practice and guidelines committee and National Society of genetic counselors practice guidelines committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of genetic counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87. Scholar
  16. 16.
    • National Comprehensive Cancer Network. Genetic/familial high risk assessment: colorectal (version 1.2018). Accessed November 11, 2018. This is guidance information from NCCN of genetic/familial syndromes associated with colorectal cancer.
  17. 17.
    Hart TL, Charles ST, Gunaratne M, Baxter NN, Cotterchio M, Cohen Z, et al. Symptom severity and quality of life among long-term colorectal cancer survivors compared with matched control subjects: a population-based study. Dis Colon Rectum. 2018;61(3):355–63. Scholar
  18. 18.
    Kunitake H, Russell MM, Zheng P, Yothers G, Land SR, Petersen L, et al. Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01. J Cancer Surviv. 2017;11(1):111–8. Scholar
  19. 19.
    Jansen L, Koch L, Brenner H, Arndt V. Quality of life among long-term (≥5 years) colorectal cancer survivors--systematic review. Eur J Cancer. 2010;46(16):2879–88. Scholar
  20. 20.
    Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(5):1228–34. Scholar
  21. 21.
    Yde J, Larsen HM, Laurberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options. Int J Color Dis. 2018;33(6):683–94. Scholar
  22. 22.
    Sun V, Grant M, Wendel CS, McMullen CK, Bulkley JE, Altschuler A, et al. Dietary and behavioral adjustments to manage bowel dysfunction after surgery in long-term colorectal cancer survivors. Ann Surg Oncol. 2015;22(13):4317–24. Scholar
  23. 23.
    El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65(6):427–55. Scholar
  24. 24.
    Visser WS, te Riele WW, Boerma D, van Ramshorst B, van Westreenen HL. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Ann Coloproctol. 2014;30(3):109–14. Scholar
  25. 25.
    Oudsten Den BL, Traa MJ, Thong MSY, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer. 2012;48(17):3161–70. Scholar
  26. 26.
    Reese JB, Finan PH, Haythornthwaite JA, Kadan M, Regan KR, Herman JM, et al. Gastrointestinal ostomies and sexual outcomes: a comparison of colorectal cancer patients by ostomy status. Support Care Cancer. 2013;22(2):461–8. Scholar
  27. 27.
    Schüring AN, Fehm T, Behringer K, Goeckenjan M, Wimberger P, Henes M, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: indications for fertility preservation. Arch Gynecol Obstet. 2017;297(1):241–55. Scholar
  28. 28.
    Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22(7):1999–2007. Scholar
  29. 29.
    Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol. 2015;33(30):3416–22. Scholar
  30. 30.
    Kenzik KM, Balentine C, Richman J, Kilgore M, Bhatia S, Williams GR. New-onset cardiovascular morbidity in older adults with stage I to III colorectal Cancer. J Clin Oncol. 2018;36(6):609–16. Scholar
  31. 31.
    Jones JM, Olson K, Catton P, Catton CN, Fleshner NE, Krzyzanowska MK, et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors. J Cancer Surviv. 2015;10(1):51–61. Scholar
  32. 32.
    •• National Comprehensive Cancer Network. Cancer-related fatigue (version 2.2018). Accessed November 11, 2018. This is guidance information from NCCN on cancer related fatigue.
  33. 33.
    Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–32. Scholar
  34. 34.
    Kim HJ, Boland PJ, Meredith DS, et al. Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation. Int J Radiat Oncol Biol Phys. 2012;84(3):694–9. Scholar
  35. 35.
    Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, et al. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009;74(3):818–23. Scholar
  36. 36.
    Holm T, Singnomklao T, Rutqvist L-E, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma: adverse effects during long term follow-up of two randomized trials. Cancer. 1996;78(5):968–76.<968::AID-CNCR5>3.0.CO;2-8.CrossRefPubMedGoogle Scholar
  37. 37.
    van den Blink QU, Garcez K, Henson CC, Davidson SE, Higham CE. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, ed. Cochrane Database Syst Rev. 2018;114(21 (Suppl 1)):344. Scholar
  38. 38.
    Nipp RD, Shui A, Kirchhoff AC, et al. Financial burden in adult cancer survivors: care affordability and accessibility. J Clin Oncol. 2016;34(15_suppl):6535. Scholar
  39. 39.
    Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2012;119(6):1257–65. Scholar
  40. 40.
    Bernard DSM, Farr SL, Fang Z. National Estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29(20):2821–6. Scholar
  41. 41.
    USA Today/Kaiser Family Foundation/Harvard School of Public Health National Survey of Households Affected by Cancer. Accessed November 11, 2018.
  42. 42.
    Zafar Y, Goetzinger AM, Fowler R, et al. Impact of out-of-pocket expenses on cancer care. J Clin Oncol. 2011;29(15_suppl):6006. Scholar
  43. 43.
    Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–90. Scholar
  44. 44.
    Nipp RD, Zullig LL, Samsa G, Peppercorn JM, Schrag D, Taylor DH Jr, et al. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. Psychooncology. 2016;25(6):719–25. Scholar
  45. 45.
    Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. Scholar
  46. 46.
    Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. 2013;32(6):1143–52. Scholar
  47. 47.
    Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30(14):1608–14. Scholar
  48. 48.
    Jagsi R, Pottow JAE, Griffith KA, Bradley C, Hamilton AS, Graff J, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32(12):1269–76. Scholar
  49. 49.
    De Souza JA, Wroblewski K, Proussaloglou E, Nicholson L, Hantel A, Wang Y. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017;35(15_suppl):6615. Scholar
  50. 50.
    Regenbogen SE, Veenstra CM, Hawley ST, Banerjee M, Ward KC, Kato I, et al. The personal financial burden of complications after colorectal cancer surgery. Cancer. 2014;120(19):3074–81. Scholar
  51. 51.
    van Muijen P, Weevers NLEC, Snels IAK, Duijts SFA, Bruinvels DJ, Schellart AJM, et al. Predictors of return to work and employment in cancer survivors: a systematic review. Eur J Cancer Care. 2013;22(2):144–60. Scholar
  52. 52.
    Taskila T, Lindbohm ML. Factors affecting cancer survivors’ employment and work ability. Acta Oncol. 2007;46(4):446–51. Scholar
  53. 53.
    Tevaarwerk AJ, Lee JW, Sesto ME, Buhr KA, Cleeland CS, Manola J, et al. Employment outcomes among survivors of common cancers: the symptom outcomes and practice patterns (SOAPP) study. J Cancer Surviv. 2013;7(2):191–202. Scholar
  54. 54.
    Tevaarwerk AJ, Lee J-W, Terhaar A, Sesto ME, Smith ML, Cleeland CS, et al. Working after a metastatic cancer diagnosis: factors affecting employment in the metastatic setting from ECOG-ACRIN’s symptom outcomes and practice patterns study. Cancer. 2016;122(3):438–46. Scholar
  55. 55.
    Yabroff KR, Guy GP, Ekwueme DU, et al. Annual patient time costs associated with medical care among cancer survivors in the United States. Med Care. 2014;52(7):594–601. Scholar
  56. 56.
    Zajacova A, Dowd JB, Schoeni RF, Wallace RB. Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer. 2015;121(24):4425–32. Scholar
  57. 57.
    Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014;10(5):332–8. Scholar
  58. 58.
    Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754–64. Scholar
  59. 59.
    Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012;104(22):1702–11. Scholar
  60. 60.
    Zhu Y, Wu H, Wang PP, Savas S, Woodrow J, Wish T, et al. Dietary patterns and colorectal cancer recurrence and survival: a cohort study. BMJ Open. 2013;3(2):e002270. Scholar
  61. 61.
    Kroenke CH, Neugebauer R, Meyerhardt J, Prado CM, Weltzien E, Kwan ML, et al. Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. JAMA Oncol. 2016;2(9):1137–45. Scholar
  62. 62.
    Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the cancer prevention study-II nutrition cohort. J Clin Oncol. 2012;30(1):42–52. Scholar
  63. 63.
    Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–54. Scholar
  64. 64.
    Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from cancer and leukemia group B 89803. J Clin Oncol. 2008;26(25):4109–15. Scholar
  65. 65.
    Gibson TM, Park Y, Robien K, Shiels MS, Black A, Sampson JN, et al. Body mass index and risk of second obesity-associated cancers after colorectal cancer: a pooled analysis of prospective cohort studies. J Clin Oncol. 2014;32(35):4004–11. Scholar
  66. 66.
    Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815–40. Scholar
  67. 67.
    Morey MC, Snyder DC, Sloane R, Cohen HJ, Peterson B, Hartman TJ, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA. 2009;301(18):1883–91. Scholar
  68. 68.
    Lynch BM, Cerin E, Owen N, Hawkes AL, Aitken JF. Prospective relationships of physical activity with quality of life among colorectal cancer survivors. J Clin Oncol. 2008;26(27):4480–7. Scholar
  69. 69.
    Arem H, Pfeiffer RM, Engels EA, Alfano CM, Hollenbeck A, Park Y, et al. Pre- and postdiagnosis physical activity, television viewing, and mortality among patients with colorectal cancer in the National Institutes of Health-AARP diet and health study. J Clin Oncol. 2015;33(2):180–8. Scholar
  70. 70.
    Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich CM, Campbell KL, Prapavessis H, et al. Effects of a structured exercise program on physical activity and fitness in Colon Cancer survivors: one year feasibility results from the CHALLENGE trial. Cancer Epidemiol Biomark Prev. 2016;25(6):969–77. Scholar
  71. 71.
    •• Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–9. This is a randomized double-blinded trial of aspirin as a chemopreventive agent against colorectal cancer. The findings of this study showed that low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel.CrossRefPubMedGoogle Scholar
  72. 72.
    Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883–90. Scholar
  73. 73.
    Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58. Scholar
  74. 74.
    Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107(9):1602–7. Scholar
  75. 75.
    McCowan C, Munro AJ, Donnan PT, Steele RJC. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49(5):1049–57. Scholar
  76. 76.
    Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJM, van Herk-Sukel MPP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–70. Scholar
  77. 77.
    Bains SJ, Mahic M, Myklebust TÅ, Småstuen MC, Yaqub S, Dørum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol. 2016;34(21):2501–8. Scholar
  78. 78.
    Zgaga L, Theodoratou E, Farrington SM, Din FVN, Ooi LY, Glodzik D, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32(23):2430–9. Scholar
  79. 79.
    Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26(18):2984–91. Scholar
  80. 80.
    Lewis C, Xun P, He K. Vitamin D supplementation and quality of life following diagnosis in stage II colorectal cancer patients: a 24-month prospective study. Support Care Cancer. 2016;24(4):1655–61. Scholar
  81. 81.
    Jeffreys M, Redaniel MT, Martin RM. The effect of pre-diagnostic vitamin D supplementation on cancer survival in women: a cohort study within the UK clinical practice research datalink. BMC Cancer. 2015;15(1):670. Scholar
  82. 82.
    Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. Cancer. 2011;117(21):4948–57. Scholar
  83. 83.
    Yang B, Jacobs EJ, Gapstur SM, Stevens V, Campbell PT. Active smoking and mortality among colorectal cancer survivors: the Cancer Prevention Study II nutrition cohort. J Clin Oncol. 2015;33(8):885–93. Scholar
  84. 84.
    Yang B, Gapstur SM, Newton CC, Jacobs EJ, Campbell PT. Alcohol intake and mortality among survivors of colorectal cancer: the Cancer prevention study II nutrition cohort. Cancer. 2017;123(11):2006–13. Scholar
  85. 85.
    •• Institute of Medicine (2005) From Cancer Patient to Cancer Survivor: Lost in Translation. This landmark Institute of Medicine report raised awareness of the medical, functional, and psychosocial consequences of cancer and its treatment.Google Scholar
  86. 86.
    Brennan ME, Gormally JF, Butow P, Boyle FM, Spillane AJ. Survivorship care plans in cancer: a systematic review of care plan outcomes. Br J Cancer. 2014;111(10):1899–908. Scholar
  87. 87.
    Jefford M, Lotfi-Jam K, Baravelli C, Grogan S, Rogers M, Krishnasamy M, et al. Development and pilot testing of a nurse-led posttreatment support package for bowel cancer survivors. Cancer Nurs. 2011;34(3):E1–E10. Scholar
  88. 88.
    Birken SA, Raskin S, Zhang Y, Lane G, Zizzi A, Pratt-Chapman M. Survivorship care plan implementation in US cancer programs: a national survey of cancer care providers. J Cancer Educ. 2018;17(4):241–9. Scholar
  89. 89.
    •• Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24(32):5117–24. The aim of this publication is to provide a rationale for survivor health care and to articulate a taxonomy of models of survivor care that is applicable to both community practices and academic institutions.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jillian Simard
    • 1
  • Suneel Kamath
    • 2
  • Sheetal Kircher
    • 2
    Email author
  1. 1.University of California, San FranciscoSan FranciscoUSA
  2. 2.Northwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations